Evidence map›Paper›PMID 28892721›Full record

ReviewDrug and alcohol dependence2017

Glial and neuroinflammatory targets for treating substance use disorders.

Ryan K Bachtell, Jermaine D Jones, Keith G Heinzerling, Patrick M Beardsley, Sandra D Comer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug and alcohol dependence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ryan K BachtellDepartment of Psychology and Neuroscience, and Center for Neuroscience, UCB 345, University of Colorado Boulder, Boulder, CO 80309, USA.
Jermaine D JonesDivision on Substance Use Disorders, New York State Psychiatric Institute and College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA.
Keith G HeinzerlingDepartment of Family Medicine and Center for Behavioral and Addiction Medicine, UCLA, Los Angeles, CA, USA.
Patrick M BeardsleyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, 410 N. 12th Street, Richmond, VA 23298, USA.
Sandra D ComerDivision on Substance Use Disorders, New York State Psychiatric Institute and College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: sdc10@cumc.columbia.edu.

Funding

PHARMACOLOGICAL TREATMENT OF MARIJUANA DEPENDENCEP50DA009236 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI KLEBER, HERBERT DAVID · 1994 to 2013
$39.4M
Training and Education CoreU54DA037842 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI LEVIN, FRANCES RUDNICK · 2014 to 2018
$14.3M
Pioglitazone for the Treatment of Opioid and of Nicotine DependenceR01DA031022 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI BISAGA, ADAM, COMER, SANDRA D · 2010 to 2013
$3.5M
Adenosine Receptor Involvement in Methamphetamine Reward and RelapseR01DA033358 · NIDA · UNIVERSITY OF COLORADO · PI BACHTELL, RYAN K · 2013 to 2017
$1.9M
Behavior, Biology, and Chemistry: Translational Research in Substance Use DisordersR13DA029347 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHARLES P FRANCE, DAVID Richard MAGUIRE · 2011 to 2026
$388k
NIDA NIH HHS P50 DA009236NIDA NIH HHS R01 DA031022NIDA NIH HHS R01 DA033358NIDA NIH HHS R13 DA029347NIDA NIH HHS U54 DA037842
6 · The paper itself

Abstract

backgroundThe plenary session at the 2016 Behavior, Biology and Chemistry: Translational Research in Addiction Conference focused on glia as potential players in the development, persistence and treatment of substance use disorders. Glia partake in various functions that are important for healthy brain activity. Drugs of abuse alter glial cell activity producing several perturbations in brain function that are thought to contribute to behavioral changes associated with substance use disorders. Consequently, drug-induced changes in glia-driven processes in the brain represent potential targets for pharmacotherapeutics treating substance use disorders.

methodsFour speakers presented preclinical and clinical research illustrating the effects that glial modulators have on abuse-related behavioral effects of psychostimulants and opioids. This review highlights some of these findings and expands its focus to include other research focused on drug-induced glia abnormalities and glia-focused treatment approaches in substance use disorders.

resultsPreclinical findings show that drugs of abuse induce neuroinflammatory signals and disrupt glutamate homeostasis through their interaction with microglia and astrocytes. Preclinical and clinical studies testing the effects of glial modulators show general effectiveness in reducing behaviors associated with substance use disorders.

conclusionsThe contribution of drug-induced glial activity continues to emerge as an intriguing target for substance use disorder treatments. Clinical investigations of glial modulators have yielded promising results on substance use measures and indicate that they are generally safe and well-tolerated. However, results have not been entirely positive and more questions remain for continued exploration in the development and testing of glial-directed treatments for substance use disorders.

Indexed as

NeurogliaAnalgesics, OpioidAstrocytesBehavior, AddictiveBrainCentral Nervous System StimulantsHumansMicrogliaSubstance-Related DisordersAnalgesics, OpioidCentral Nervous System StimulantsAlcoholAstrocyteCocaineCytokineGlutamateInflammatoryInnate immuneMicrogliaMorphineOpioidPsychostimulant

Identifiers

PMID28892721
PMCPMC5790191

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.